Impact of Dolutegravir based ART among Indian women

International Workshop on HIV & Women 2020

Adolescent girls and young women: should they be formally recognized as a key population for HIV?

International Workshop on HIV & Women 2020

Maternal and cord plasma bioactive eicosanoid profiles differ in pregnant women living with HIV compared to HIV-negative pregnant women

International Workshop on HIV & Women 2020

Women on anti-retroviral therapy (ART) are less likely to achieve HIV RNA <50 copies/ml compared to men – Real World Data from the National Swedish InfCareHIV Cohort

International Workshop on HIV & Women 2020

Not recommended, but done: Breastfeeding with HIV in Germany

International Workshop on HIV & Women 2020

Determinants of PrEP initiation in women at high risk for HIV

International Workshop on HIV & Women 2020

Validating incident pregnancies among women using contraceptives and antiretrovirals

International Workshop on HIV & Women 2020

Post-Exposure Prophylaxis in victims of sexual violence. Experience at the Condesa Specialized Clinic (CSC)

International Workshop on HIV & Women 2020

Examining differences in syndemic factors by gender and sexual orientation among women, straight men, and gay, bisexual, and other men who have sex with men living with HIV in British Columbia, Canada

International Workshop on HIV & Women 2020

CD4:CD8 ratio normalization among treatment naive women

International Workshop on HIV & Women 2020

Attitudes towards health, sexual intimacy, and child-bearing among women living with HIV in 24 countries

International Workshop on HIV & Women 2020

Differences by gender and sexual orientation in treatment satisfaction and aspirations among persons living with HIV

International Workshop on HIV & Women 2020

Gender, equality, and empowered decision making in HIV care

International Workshop on HIV & Women 2020

Impact of microbial exposures on HPV immune titers and infection among HPV-vaccinated women living with HIV

International Workshop on HIV & Women 2020

Women race, age and regional US & non-US subgroup analysis of dolutegravir (DTG) and non-integrase inhibitor treatment (non-INSTI) regimens in naïve randomized clinical trials at Week 48.

International Workshop on HIV & Women 2020

ATLAS and FLAIR: efficacy, pharmacokinetics and reasons for satisfaction in women with cabotegravir & rilpivirine long acting regimen at week 48

International Workshop on HIV & Women 2020

Dolutegravir-containing ART does not reduce etonogestrel implant concentrations

International Workshop on HIV & Women 2020

Cabotegravir: Assessment of reproductive and developmental toxicity in animal studies1

International Workshop on HIV & Women 2020

Achieving the third 95: Keeping adolescents living with HIV virally suppressed in rural Nigeria in test and treat era using Continuous Quality Improvement Model of Peer Counseling & Support Group

International Workshop on HIV & Women 2020

Cabotegravir pharmacokinetic tail in pregnancy and neonatal outcomes

International Workshop on HIV & Women 2020

Timing of HIV diagnosis in HIV-positive pregnant women giving birth in a high prevalence Russian region

International Workshop on HIV & Women 2020

Mode of birth among women living with HIV: A population-based retrospective cohort study

International Workshop on HIV & Women 2020

Prevalence of polypharmacy and medication use contraindicated during pregnancy among a cohort of women living with HIV who are of childbearing age, 2016-2017.

International Workshop on HIV & Women 2020

Clinical trial simulation to improve HIV pre-exposure prophylaxis dosing in pregnancy

International Workshop on HIV & Women 2020